Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Phase 2

Completed

Conditions: Active Ulcerative Colitis

Interventions: Drug: Placebo
Drug: BG9418 (Interferon beta-1a)

First Posted Date: 2008-02-15

Last Posted Date: 2014-08-13

Lead Sponsor: Biogen

Target Recruit Count: 123

Registration Number: NCT00616434

Locations: 🇸🇰
Investigator, Trencin, Slovakia
🇷🇺
Investiator, Yaroslavl, Russian Federation

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1a

First Posted Date: 2008-01-23

Last Posted Date: 2010-01-27

Lead Sponsor: Biogen

Target Recruit Count: 136

Registration Number: NCT00599274

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇨🇦
Coordinating Research Site, Halifax, Nova Scotia, Canada

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: IDEC-114

First Posted Date: 2007-12-17

Last Posted Date: 2012-06-08

Lead Sponsor: Biogen

Target Recruit Count: 42

Registration Number: NCT00575068

Locations: 🇺🇸
Research Site, Durham, North Carolina, United States

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Phase 4

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Interferon beta-1a

First Posted Date: 2007-12-14

Last Posted Date: 2008-09-04

Lead Sponsor: Biogen

Target Recruit Count: 19

Registration Number: NCT00574041

Locations: 🇦🇺
Coordinating Research Site, Malvern, Victoria, Australia

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Phase 1

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions: Drug: natalizumab
Other: standard of care

First Posted Date: 2007-11-16

Last Posted Date: 2014-09-09

Lead Sponsor: Biogen

Target Recruit Count: 76

Registration Number: NCT00559702

Locations: 🇺🇸
Research Site, Vienna, Virginia, United States

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BIIB022

First Posted Date: 2007-11-09

Last Posted Date: 2017-01-09

Lead Sponsor: Biogen

Target Recruit Count: 40

Registration Number: NCT00555724

Locations: 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Biological: keyhole limpet hemocyanin (KLH)
Biological: BG00002 (natalizumab)
Biological: tetanus diphtheria toxoid vaccine (Td)

First Posted Date: 2007-09-27

Last Posted Date: 2017-02-15

Lead Sponsor: Biogen

Target Recruit Count: 60

Registration Number: NCT00536120

Locations: 🇺🇸
Research Site 4, Charleston, West Virginia, United States
🇺🇸
Research Site 3, Charlotte, North Carolina, United States
🇺🇸
Research Site 1, Fullerton, California, United States

and more 4 locations

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Interferon beta-1a

First Posted Date: 2007-09-24

Last Posted Date: 2007-12-13

Lead Sponsor: Biogen

Target Recruit Count: 284

Registration Number: NCT00534261

Locations: 🇬🇧
Coordinating Research Site, Glasgow, Scotland, United Kingdom

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB014
Other: [11C]SCH442416

First Posted Date: 2007-09-18

Last Posted Date: 2008-07-30

Lead Sponsor: Biogen

Target Recruit Count: 32

Registration Number: NCT00531193

Locations: 🇬🇧
Research Site, London, United Kingdom

Avonex 15 Year Long Term Follow-up Study

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2007-09-05

Last Posted Date: 2010-03-08

Lead Sponsor: Biogen

Target Recruit Count: 122

Registration Number: NCT00525343

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

and more 1 locations

Home Terms & Conditions Privacy Policy